TARSTarsus Pharmaceuticals, Inc.
$70.85+3.0% 1Y
$70.85
$56.1352 weeks$90.81
The business
How TARS's business earns
Tarsus Pharmaceuticals, Inc. spent more than it took in: an operating loss of $696M on $682M of revenue, 12 months to Sep 30, 2026.
$696M
Operating loss · on $682M of revenue · 12 months to Sep 30, 2026
- Share count, year on year
- +8.9%
Share count, year on year · more shares than a year ago
- R&D as % of revenue
- 17%
R&D as % of revenue
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2021 | −21% |
| FY2022 | −243% |
| FY2023 | −821% |
| FY2024 | −66% |
| FY2025 | −16% |
Details›
- Operating margin12 months to Sep 30, 2026
- −102%
- Net margin12 months to Sep 30, 2026
- −103%
- Free cash flow margin
- 4.8%
- R&D as % of revenue
- 17%
- Revenue, trailing twelve months
- $682M
- Free cash flow, trailing twelve months
- $32M
- Net income, trailing twelve months
- −$702M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from TARS and who it buys from, as the companies report it.
Customerswho buys
- Major customers74%
Combined share of revenue · FY2025 10-K
Supplierswho it buys from
None disclosed.
On our screensPrice implies 20 percent a year growth
Biotechnology
The closest names by size in the same industry